Target to $148 from $135
Tuesday, April 11, 2023
ReShape: Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
https://finance.yahoo.com/news/reshape-lifesciences-receives-notice-allowance-123000860.html
Rumors of Acquisition Surrounding Aldeyra
As of April 11, 2023, word on the street is that a significant pharmaceutical company has its sights set on acquiring Aldeyra Therapeutics, a biotech firm specializing in immune-mediated disease treatments. While Aldeyra recently wrapped up its Phase 2 clinical trial of an orally administered RASP modulator, there has been no official word on the acquisition rumor. The company only proposed a public offering of common stock in February of this year.
https://beststocks.com/rumors-of-acquisition-surrounding-aldeyra-the/
Akebia Adjourns Special Meeting of Stockholders
Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it adjourned, without conducting any business, the special meeting of stockholders (the "Special Meeting") on Tuesday, April 11, 2023 to allow the company to solicit from its stockholders the additional proxies necessary to obtain approval of the proposals described in the company's revised definitive proxy statement filed with the Securities and Exchange Commission on March 17, 2023.
The Special Meeting will reconvene on Thursday, May 4, 2023, beginning at 10:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/AKBA2023SM. The record date for the Special Meeting continues to be the close of business on February 16, 2023. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. The proxy statement is available at https://www.sec.gov/ and at www.proxyvote.com.
Akebia encourages all stockholders of record at the close of business on February 16, 2023 who have not yet voted, to vote by 11:59 p.m. Eastern Time on May 3, 2023.
Akebia's board of directors strongly recommends that stockholders vote "FOR" each of the proposals presented at the Special Meeting.
https://finance.yahoo.com/news/akebia-therapeutics-announces-adjournment-special-151500531.html
Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight
A U.S. appeals court handed Moderna Inc a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp patent related to the companies' legal fight over Moderna's blockbuster COVID-19 vaccines.
The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal's ruling that the patent for Arbutus' lipid nanoparticle (LNP) technology was invalid based on an earlier Arbutus patent that disclosed the same invention.
Moderna challenged the patent at the PTO's Patent Trial and Appeal Board in 2018, and the board invalidated it in 2019.
A spokesperson for Genevant declined to comment on the Tuesday decision. A Moderna spokesperson said the company was pleased with the ruling.
The Federal Circuit's decision does not affect an ongoing lawsuit filed by Arbutus and Genevant Sciences — a joint venture between Arbutus and Roivant Sciences Ltd — against Moderna last year in Delaware for allegedly infringing other related LNP patents.
Warminster Township, Pennsylvania-based Arbutus said in the lawsuit that Cambridge, Massachusetts-based Moderna began challenging its patents at the PTO after failing to acquire a license to its LNP technology.
The technology is used to deliver RNA to target cells without being attacked by the body's immune system.
Arbutus separately sued Pfizer and BioNTech for patent infringement last week over their COVID-19 shots, in a lawsuit that also does not include the canceled patent.
The Federal Circuit case is Arbutus Biopharma Corp v. ModernaTX Inc, U.S. Court of Appeals for the Federal Circuit, No. 20-1183.
https://finance.yahoo.com/news/1-moderna-fends-off-arbutus-193001506.html
Altamira: 'mRNA Delivery Platform Versatile and Efficient Alternative to Lipid Nanoparticles'
Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and non-toxic, enabling delivery to extrahepatic targets and efficient endosomal release
Continued momentum in mRNA vaccines and therapeutics with over 840 programs under development, according to fresh data from Beacon RNA database by Hanson Wade
Limitations of hitherto dominant lipid nanoparticle (LNP) technologies call for alternate mRNA delivery solutions
Innovative Eyewear. Launches 1st ChatGPT Enabled Smart Eyewear
Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer and retailer of smart eyewear under the Lucyd®, Nautica®, and Eddie Bauer® brands, announces today that it has launched a new iOS/Android app called Lucyd. The Lucyd app enables a voice interface for ChatGPT on our smart eyewear. The user can ask questions to ChatGPT through microphones already built into our glasses and hear the responses through their stereo speakers. The app is device agnostic and works with many other hearables, including, but not limited to, AirPods®1. Additionally, the app may be used via a streamlined visual interface on any smartphone to enhance accessibility.
"We are excited to be the first company to provide ChatGPT enabled smart eyewear. With our new Lucyd app, which is free to our eyewear customers, we are continuing to make smart eyewear more accessible and functional than ever before," says Harrison Gross, CEO of Innovative Eyewear. "A great pair of smartglasses is defined by three key factors: fashion, tech, and suitability for all-day wear. The Lyte 2.0 collection successfully addresses these factors and now provides access to the world's most popular AI assistant. By connecting to ChatGPT with your voice on Lucyd smart eyewear, you can access a wealth of detailed research on just about any subject, making it one of the most powerful mobile learning systems available."
As recently announced, Lucyd Lyte® 2.0 eyewear is now available in 15 distinct styles, which we believe is the most of any smart eyewear on the US market. With the Lucyd app, all of these frames provide on-the-go access to ChatGPT. Lucyd smart eyewear makes it easy to use ChatGPT by combining the strength of a natural language AI bot with the natural ergonomic interface of speaking and listening on a handsfree wearable.
https://finance.yahoo.com/news/innovative-eyewear-inc-launches-first-110000390.html
Subscribe to:
Posts (Atom)